PMID- 29056549
OWN - NLM
STAT- MEDLINE
DCOM- 20190318
LR  - 20190318
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 20
IP  - 1
DP  - 2018 Jan
TI  - Adoptive transfer of natural killer cells in combination with chemotherapy 
      improves outcomes of patients with locally advanced colon carcinoma.
PG  - 134-148
LID - S1465-3249(17)30708-9 [pii]
LID - 10.1016/j.jcyt.2017.09.009 [doi]
AB  - BACKGROUND: Despite the availability of multiple treatment strategies, patients 
      with advanced colon carcinoma (CC) have poor prognoses. The aim of this study was 
      to evaluate the efficacy and safety of natural killer (NK) cell therapy in 
      combination with chemotherapy in patients with locally advanced CC. METHODS: We 
      assessed the cytotoxicity of NK cells to CC cells (CCs) and CC stem cells (CSCs) 
      pre-treated with 5-fluorouracil or oxaliplatin in vitro. Then, an open-label 
      cohort study was conducted with locally advanced CC patients who had received 
      radical resection. Patients received either NK cell therapy combined with 
      chemotherapy (NK cell group, 27 patients) or pure chemotherapy (control group, 33 
      patients). Progression-free survival (PFS), overall survival (OS) and adverse 
      effects were investigated. RESULTS: Chemotherapy sensitized CCs and CSCs to NK 
      cell cytotoxicity through regulation of NK cell-activating/inhibitory receptor 
      ligands. Poorly differentiated CCs were more susceptible to NK cells than 
      well-differentiated ones. In the cohort study, the 5-year PFS and OS rates in the 
      NK cell group were significantly higher than those in the control group (51.1% 
      versus 35%, P= 0.044; 72.5% versus 51.6%, P= 0.037, respectively). Among patients 
      with poorly differentiated carcinomas and low expression of human leukocyte 
      antigen (HLA)-1, the median PFS in the NK cell group versus the control group was 
      23.5 versus 12.1 months (P= 0.0475) and 33.1 versus 18.5 months (P= 0.045), 
      respectively. No significant adverse reactions were reported. CONCLUSION: NK cell 
      therapy in combination with chemotherapy in locally advanced CC prevented 
      recurrence and prolonged survival with acceptable adverse effects, especially for 
      poorly differentiated carcinomas.
CI  - Copyright (c) 2017 International Society for Cellular Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Li, Lingyu
AU  - Li L
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Li, Wei
AU  - Li W
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Wang, Chang
AU  - Wang C
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Yan, Xu
AU  - Yan X
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Wang, Yizhuo
AU  - Wang Y
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Niu, Chao
AU  - Niu C
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Zhang, Xiaoying
AU  - Zhang X
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Li, Min
AU  - Li M
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Tian, Huimin
AU  - Tian H
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Yao, Cheng
AU  - Yao C
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Jin, Haofan
AU  - Jin H
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Han, Fujun
AU  - Han F
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Xu, Dongsheng
AU  - Xu D
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Han, Wei
AU  - Han W
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Li, Dan
AU  - Li D
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China.
FAU - Cui, Jiuwei
AU  - Cui J
AD  - Cancer Center, The First Hospital of Jilin University, Changchun, China. 
      Electronic address: cuijw@jlu.edu.cn.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171019
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Ligands)
SB  - IM
MH  - Cell Differentiation
MH  - Cell Line, Tumor
MH  - Cohort Studies
MH  - Colonic Neoplasms/drug therapy/*pathology/*therapy
MH  - Cytotoxicity, Immunologic
MH  - Female
MH  - Humans
MH  - *Immunotherapy, Adoptive/adverse effects
MH  - Killer Cells, Natural/immunology/*transplantation
MH  - Ligands
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/pathology
MH  - Neoplasm Staging
MH  - Neoplastic Stem Cells/pathology
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Treatment Outcome
OTO - NOTNLM
OT  - chemotherapy
OT  - colon cancer
OT  - natural killer cell therapy
EDAT- 2017/10/24 06:00
MHDA- 2019/03/19 06:00
CRDT- 2017/10/24 06:00
PHST- 2017/01/06 00:00 [received]
PHST- 2017/09/14 00:00 [revised]
PHST- 2017/09/14 00:00 [accepted]
PHST- 2017/10/24 06:00 [pubmed]
PHST- 2019/03/19 06:00 [medline]
PHST- 2017/10/24 06:00 [entrez]
AID - S1465-3249(17)30708-9 [pii]
AID - 10.1016/j.jcyt.2017.09.009 [doi]
PST - ppublish
SO  - Cytotherapy. 2018 Jan;20(1):134-148. doi: 10.1016/j.jcyt.2017.09.009. Epub 2017 
      Oct 19.